https://mindmedicinelaw.com/briefing/mdma-prescription-authorized-in-new-zealand-regulatory-and-clinical-implications-20260905-39177The Psychedelic Journalen2026-09-05T22:04:08.878199+00:00MDMA Prescription Authorized in New Zealand: Regulatory and Clinical Implicationsmdma prescription, new zealand psychedelic policy, psychiatrist authorization, clinical implementation, regulatory pathway, post-marketing surveillance, insurance coverage, psychedelic medicine, adverse event reportinghttps://mindmedicinelaw.com/briefing/mdma-prescribing-for-ptsd-us-federal-policy-breakthrough-20260905-39009The Psychedelic Journalen2026-09-05T15:05:01.161537+00:00MDMA Prescribing for PTSD: US Federal Policy Breakthroughmdma, ptsd, fda approval, psychedelic therapy, drug policy, clinical trials, risk evaluation, rem program, market access, mental healthhttps://mindmedicinelaw.com/briefing/fda-approves-mdma-for-ptsd-policy-clinical-and-market-impact-20260904-39176The Psychedelic Journalen2026-09-05T22:03:55.927555+00:00FDA Approves MDMA for PTSD: Policy, Clinical, and Market Impactmdma approval, fda, ptsd treatment, psychedelic policy, clinical trials, insurance coverage, dea rescheduling, risk evaluation, market structure, mental healthhttps://mindmedicinelaw.com/briefing/geriatric-mental-health-precision-approaches-and-psychedelic-trial-gaps-20260904-38933The Psychedelic Journalen2026-09-05T15:06:43.662920+00:00Geriatric Mental Health: Precision Approaches and Psychedelic Trial Gapsgeriatric psychiatry, late-life depression, psychedelic clinical trials, ketamine, precision medicine, caregiver burden, older adults, polypharmacy, integrated care models, regulatory sciencehttps://mindmedicinelaw.com/briefing/mdma-assisted-couples-therapy-for-ptsd-u-s-pilot-trial-insights-20260904-38909The Psychedelic Journalen2026-09-05T15:06:05.052332+00:00MDMA-Assisted Couples Therapy for PTSD: U.S. Pilot Trial Insightsmdma-assisted therapy, ptsd, veterans, couples therapy, clinical trials, cognitive-behavioral conjoint therapy, psychedelic research, relationship outcomes, public health, regulatory policyhttps://mindmedicinelaw.com/briefing/federal-report-urges-states-to-prepare-for-fda-psychedelic-approvals-20260904-38841The Psychedelic Journalen2026-09-04T22:04:30.448364+00:00Federal Report Urges States to Prepare for FDA Psychedelic Approvalsfederal psychedelic policy, FDA approval psychedelics, state law harmonization, clinical trial blinding, THC active placebo, mental health regulation, psychedelic infrastructure, regulatory readiness, MDMA psilocybin trialshttps://mindmedicinelaw.com/briefing/new-zealand-approves-mdma-for-ptsd-policy-and-clinical-implications-20260904-38842The Psychedelic Journalen2026-09-04T22:04:10.016650+00:00New Zealand Approves MDMA for PTSD: Policy and Clinical Implicationsmdma approval new zealand, ptsd treatment, psychedelic policy, clinical trials mdma, medsafe regulation, international drug policy, mental health innovation, adverse event monitoring, equity in psychedelic carehttps://mindmedicinelaw.com/briefing/va-psilocybin-trial-in-alabama-policy-and-clinical-implications-20260904-38672The Psychedelic Journalen2026-09-04T15:07:16.305977+00:00VA Psilocybin Trial in Alabama: Policy and Clinical Implicationsva psilocybin trial, alabama veterans mental health, psychedelic clinical research, federal policy on psychedelics, treatment-resistant ptsd, psychedelic therapy risks, veterans affairs research, conservative state drug policy, psilocybin-assisted therapy, clinical trial diversityhttps://mindmedicinelaw.com/briefing/md-anderson-launches-psilocybin-trial-for-chemotherapy-neurotoxicity-20260904-38673The Psychedelic Journalen2026-09-04T15:06:33.520945+00:00MD Anderson Launches Psilocybin Trial for Chemotherapy Neurotoxicitypsilocybin, chemotherapy-induced neurotoxicity, MD Anderson Cancer Center, clinical trials, oncology supportive care, FDA regulation, psychedelic research, peripheral neuropathy, neuroprotection, drug-drug interactionshttps://mindmedicinelaw.com/briefing/new-zealand-approves-mdma-therapy-for-severe-ptsd-policy-and-practice-20260904-38670The Psychedelic Journalen2026-09-04T15:06:06.095378+00:00New Zealand Approves MDMA Therapy for Severe PTSD: Policy and Practicemdma approval new zealand, ptsd treatment policy, psychedelic-assisted therapy, medsafe regulation, asia-pacific drug policy, clinical trial data mdma, post-market surveillance, mental health innovationhttps://mindmedicinelaw.com/briefing/enigma-ptsd-consortium-maps-amygdala-hippocampus-connectivity-20260903-38892The Psychedelic Journalen2026-09-05T22:04:43.812786+00:00ENIGMA PTSD Consortium Maps Amygdala-Hippocampus Connectivityenigma ptsd consortium, amygdala hippocampus connectivity, ptsd neuroimaging, psychedelic clinical trials, biomarker development, functional connectivity, multi-site study, trauma-related disorders, regulatory sciencehttps://mindmedicinelaw.com/briefing/stress-dependent-serotonergic-and-dopaminergic-anxiety-mechanisms-implications-f-20260903-38893The Psychedelic Journalen2026-09-05T22:04:31.777798+00:00Stress-Dependent Serotonergic and Dopaminergic Anxiety Mechanisms: Implications for Psychedelic Trial Designserotonin, dopamine, stress intensity, anxiety mechanisms, psychedelic trials, biomarkers, patient stratification, zebrafish model, clinical trial designhttps://mindmedicinelaw.com/briefing/ketamine-for-refractory-opioid-withdrawal-case-report-signals-research-need-20260903-38936The Psychedelic Journalen2026-09-05T22:04:20.646379+00:00Ketamine for Refractory Opioid Withdrawal: Case Report Signals Research Needketamine, opioid withdrawal, buprenorphine, precipitated withdrawal, case report, addiction medicine, clinical research, public health, NMDA antagonist, FDAhttps://mindmedicinelaw.com/briefing/multi-omics-in-treatment-resistant-depression-translational-pathways-and-limits-20260903-38939The Psychedelic Journalen2026-09-05T15:06:55.638369+00:00Multi-Omics in Treatment-Resistant Depression: Translational Pathways and Limitsmulti-omics, treatment-resistant depression, pharmacogenomics, psychedelic trials, biomarkers, clinical utility, machine learning, therapeutic drug monitoring, translational framework, depression researchhttps://mindmedicinelaw.com/briefing/best-practice-ketamine-protocols-for-depression-regulatory-and-clinical-guidance-20260903-38938The Psychedelic Journalen2026-09-05T15:05:52.856341+00:00Best-Practice Ketamine Protocols for Depression: Regulatory and Clinical Guidance (2026)ketamine depression, esketamine, subcutaneous ketamine, oral ketamine, nasal ketamine, off-label use, psychiatric protocols, regulatory guidance, insurance coverage, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/oregon-s-psilocybin-program-early-outcomes-and-policy-impact-20260903-39011The Psychedelic Journalen2026-09-05T15:05:39.057935+00:00Oregon's Psilocybin Program: Early Outcomes and Policy Impactoregon psilocybin program, regulated psychedelic access, public health policy, psilocybin efficacy, implementation challenges, clinical outcomes, psychedelic law, adult use models, facilitator protocolshttps://mindmedicinelaw.com/briefing/cyb004-deuterated-dmt-phase-1-results-safety-duration-and-pk-challenges-20260903-38890The Psychedelic Journalen2026-09-05T15:05:25.290590+00:00CYB004 (Deuterated DMT) Phase 1 Results: Safety, Duration, and PK Challengescyb004, deuterated dmt, phase 1 trial, pharmacokinetics, psychedelic safety, tryptamine analogues, clinical development, dose variability, intravenous administrationhttps://mindmedicinelaw.com/briefing/new-zealand-approves-mdma-prescribing-for-ptsd-policy-shift-20260903-39010The Psychedelic Journalen2026-09-05T15:05:13.361879+00:00New Zealand Approves MDMA Prescribing for PTSD: Policy Shiftmdma, ptsd, new zealand, psychiatry, psychedelic medicine, clinical access, regulation, policy, public health, real-world evidencehttps://mindmedicinelaw.com/briefing/11-hsd-enzymes-and-ptsd-implications-for-neurobiology-and-future-psychiatric-tri-20260903-38592The Psychedelic Journalen2026-09-04T22:05:23.931422+00:0011β-HSD Enzymes and PTSD: Implications for Neurobiology and Future Psychiatric Trials11β-hsd, glucocorticoid metabolism, ptsd, psychiatric drug development, biomarkers, clinical trial design, neuroimaging, trauma research, psychedelic-assisted therapyhttps://mindmedicinelaw.com/briefing/drosophila-models-illuminate-sleep-impairments-in-stimulant-use-disorder-researc-20260903-38568The Psychedelic Journalen2026-09-04T22:04:59.513440+00:00Drosophila Models Illuminate Sleep Impairments in Stimulant Use Disorder Researchdrosophila models, stimulant use disorder, sleep impairment, dopamine system, preclinical neuroscience, psychedelic-assisted therapy, genetic pathways, translational research, pharmacological targetshttps://mindmedicinelaw.com/briefing/psilocybin-and-chemotherapy-nerve-injury-new-preclinical-data-from-ut-md-anderso-20260903-38844The Psychedelic Journalen2026-09-04T22:04:46.121531+00:00Psilocybin and Chemotherapy Nerve Injury: New Preclinical Data from UT MD Andersonpsilocybin, chemotherapy-induced neuropathy, preclinical research, supportive oncology, neuroprotection, translational neuroscience, drug policy, FDA regulation, psychedelic researchhttps://mindmedicinelaw.com/briefing/mdma-prescribing-approved-for-ptsd-u-s-policy-and-clinical-implications-20260903-38843The Psychedelic Journalen2026-09-04T22:03:47.652197+00:00MDMA Prescribing Approved for PTSD: U.S. Policy and Clinical Implicationsmdma approval, ptsd treatment, fda policy, psychiatric prescribing, drug rescheduling, clinical trials, risk evaluation, insurance coverage, psychedelic therapy, mental health regulationhttps://mindmedicinelaw.com/briefing/silent-synapse-activation-mechanisms-and-clinical-prospects-20260903-38593The Psychedelic Journalen2026-09-04T15:07:55.563945+00:00Silent Synapse Activation: Mechanisms and Clinical Prospectssilent synapse activation, neuroplasticity, depression, addiction, psychedelic research, clinical translation, AMPAR, NMDAR, optogenetics, brain imaginghttps://mindmedicinelaw.com/briefing/psychedelics-ketamine-and-cannabinoids-for-opioid-use-disorder-us-policy-and-cli-20260903-38548The Psychedelic Journalen2026-09-04T15:07:36.541041+00:00Psychedelics, Ketamine, and Cannabinoids for Opioid Use Disorder: US Policy and Clinical Evidence Reviewopioid use disorder, psychedelics, ketamine, cannabinoids, ibogaine, regulatory policy, clinical trials, safety, neuroplasticity, public healthhttps://mindmedicinelaw.com/briefing/bi-1569912-phase-1-results-glun2b-nam-safety-in-germany-japan-20260902-38594The Psychedelic Journalen2026-09-04T22:05:39.352486+00:00BI 1569912 Phase 1 Results: GluN2B NAM Safety in Germany & Japanbi 1569912, glun2b nmda modulator, phase 1 clinical trials, neuropsychiatric drug development, safety and tolerability, non-hallucinogenic cns therapeutics, germany, japan, pharmacokinetics, policy implicationshttps://mindmedicinelaw.com/briefing/ketamine-s-antidepressive-effects-in-refractory-bipolar-depression-clinical-tria-20260902-38674The Psychedelic Journalen2026-09-04T15:08:14.248430+00:00Ketamine’s Antidepressive Effects in Refractory Bipolar Depression: Clinical Trial Insightsketamine, bipolar depression, treatment-resistant mood disorders, clinical trials, FDA regulation, off-label use, antidepressant mechanisms, psychiatric safety, policy implications, real-world evidencehttps://mindmedicinelaw.com/briefing/nutrition-s-impact-on-5-meo-dmt-clinical-trials-methodological-guidance-20260901-38932The Psychedelic Journalen2026-09-05T22:04:55.531958+00:00Nutrition’s Impact on 5-MeO-DMT Clinical Trials: Methodological Guidance5-meo-dmt, nutrition in clinical trials, psychedelic research, trial methodology, pharmacokinetics, cytochrome p450, participant safety, regulatory guidance, data reproducibilityhttps://mindmedicinelaw.com/briefing/psilocybin-review-pharmacology-safety-and-clinical-outlook-2026-20260901-38902The Psychedelic Journalen2026-09-05T15:06:20.134012+00:00Psilocybin Review: Pharmacology, Safety, and Clinical Outlook (2026)psilocybin review, pharmacology, clinical trials, safety profile, drug interactions, microdosing, regulatory barriers, psychedelic therapy, neuroplasticity, ethicshttps://mindmedicinelaw.com/briefing/subcutaneous-ketamine-for-treatment-resistant-depression-a-case-report-from-braz-20260901-38603The Psychedelic Journalen2026-09-04T22:05:52.156466+00:00Subcutaneous Ketamine for Treatment-Resistant Depression: A Case Report from Brazilsubcutaneous ketamine, treatment-resistant depression, case report, alternative delivery methods, clinical trials, psychiatric policy, Brazil, NMDA antagonist, public health accesshttps://mindmedicinelaw.com/briefing/mapping-human-thalamus-function-seeg-insights-for-psychedelic-research-20260901-38587The Psychedelic Journalen2026-09-04T15:08:31.459207+00:00Mapping Human Thalamus Function: SEEG Insights for Psychedelic Researchthalamus, stereoelectroencephalography, thalamo-cortical circuits, psychedelic research, neuromodulation, clinical trial design, epilepsy, functional brain mapping, direct electrical stimulation, translational neurosciencehttps://mindmedicinelaw.com/briefing/phase-1-results-oral-ketamir-2-safety-and-pk-in-neuropathic-pain-20260901-38588The Psychedelic Journalen2026-09-04T15:06:53.425441+00:00Phase 1 Results: Oral Ketamir-2 Safety and PK in Neuropathic Painketamir-2, nmda antagonist, phase 1 trial, oral formulation, neuropathic pain, safety profile, pharmacokinetics, non-opioid therapeutics, dissociative risk, clinical developmenthttps://mindmedicinelaw.com/briefing/ketamine-induced-bladder-injury-in-children-clinical-and-policy-implications-20260831-38997The Psychedelic Journalen2026-09-05T22:05:06.676475+00:00Ketamine-Induced Bladder Injury in Children: Clinical and Policy Implicationsketamine bladder injury, paediatric cystitis, ketamine safety, pediatric pharmacovigilance, clinical monitoring protocols, off-label ketamine use, policy implications, adverse drug reactions, bladder toxicity, emerging riskshttps://mindmedicinelaw.com/briefing/dea-s-federal-rescheduling-questions-implications-for-psychedelics-policy-in-the-20260831-38671The Psychedelic Journalen2026-09-04T15:08:48.408064+00:00DEA’s Federal Rescheduling Questions: Implications for Psychedelics Policy in the U.S.dea marijuana rescheduling, psychedelics policy, federal regulation, controlled substances act, compliance requirements, clinical research, registration process, diversion controls, legal implications, future of psychedelicshttps://mindmedicinelaw.com/briefing/ketamine-induced-memory-dysfunction-mechanisms-and-clinical-policy-implications-20260830-38651The Psychedelic Journalen2026-09-04T15:09:02.451023+00:00Ketamine-Induced Memory Dysfunction: Mechanisms and Clinical Policy Implicationsketamine, memory dysfunction, NMDA receptor, synaptic plasticity, clinical protocols, policy implications, cognitive side effects, psychiatric treatment, regulatory guidancehttps://mindmedicinelaw.com/briefing/us-oncology-providers-and-psychedelic-therapy-2026-survey-insights-20260828-38980The Psychedelic Journalen2026-09-05T22:05:18.145354+00:00US Oncology Providers and Psychedelic Therapy: 2026 Survey Insightsoncology providers, psychedelic-assisted therapy, cancer care, clinical adoption barriers, regulatory policy, provider education, phase III trials, public health, reimbursement, us healthcarehttps://mindmedicinelaw.com/briefing/state-psilocybin-regulation-comparative-policy-analysis-2026-20260825-38993The Psychedelic Journalen2026-09-05T15:06:32.205622+00:00State Psilocybin Regulation: Comparative Policy Analysis (2026)psilocybin regulation, state policy comparison, oregon measure 109, colorado natural medicine act, public health oversight, market structure, access and equity, regulatory challenges, psychedelic law, clinical research policy